MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15051990

Медицинская библиотека · Journal of clinical medicine · 2026

sFlt-1/PlGF Ratio as a Central Biomarker for Preeclampsia and Perinatal Outcomes: A Multisystem Retrospective Cohort Study.

Tătaru-Copos Anca, Huniadi Anca Carmen, Negrini Rodica Georgeta, Popescu Mircea Ioachim, Trif Paula, Murvai Gelu Florin, Galiș Radu, Sava Cristian, Szasz Florin, Murvai Romina Viorela

СтатьяПеревод пока не подготовлен

Аннотация

Background

Preeclampsia is a major cause of maternal and perinatal morbidity, characterized by placental dysfunction and angiogenic imbalance. The soluble fms-like tyrosine kinase-1-to-placental growth factor (sFlt-1/PlGF) ratio has emerged as a promising biomarker for preeclampsia; however, its prognostic value for maternal and neonatal outcomes remains incompletely defined.

Methods

This retrospective cohort study included 320 pregnant women, of whom 68 were diagnosed with preeclampsia, and 252 served as non-preeclamptic controls. Maternal serum sFlt-1 and PlGF levels were measured after 20 weeks of gestation at the time of clinical evaluation for suspected hypertensive disorders of pregnancy. Group comparisons, effect size analysis, receiver operating characteristic (ROC) curve analysis, and multivariable regression models were used to assess diagnostic performance and associations with maternal and neonatal outcomes.

Results

The sFlt-1/PlGF ratio was significantly higher in women with preeclampsia compared with non-preeclamptic pregnancies (58.5 ± 17.3 vs. 34.6 ± 19.0; p < 0.001; Cohen's d = 1.31). ROC analysis demonstrated good discriminative ability for preeclampsia (AUC = 0.81, 95% CI: 0.75-0.87), with a high negative predictive value. Increasing sFlt-1/PlGF values were independently associated with earlier gestational age at delivery, lower birth weight, reduced Apgar (Appearance, Pulse, Grimace, Activity, and Respiration) score, and a higher likelihood of neonatal intensive care unit admission.

Conclusions

The sFlt-1/PlGF ratio is a robust biomarker for preeclampsia, providing both diagnostic discrimination and prognostic information regarding maternal and neonatal outcomes. Its integration into clinical practice may support clinical risk awareness when interpreted in the context of standard clinical evaluation and support informed decision-making in pregnancies with suspected or confirmed preeclampsia.

Для цитирования: Tătaru-Copos Anca, Huniadi Anca Carmen, Negrini Rodica Georgeta, Popescu Mircea Ioachim, Trif Paula, Murvai Gelu Florin, Galiș Radu, Sava Cristian, Szasz Florin, Murvai Romina Viorela. sFlt-1/PlGF Ratio as a Central Biomarker for Preeclampsia and Perinatal Outcomes: A Multisystem Retrospective Cohort Study.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15051990.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.